- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03628222
Transbronchial Lung Biopsy Guided by ENB
Transbronchial Lung Biopsy Guided by Electromagnetic Navigation Bronchoscopy: A Prospective, Randomized, Multicenter, Superiority Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shiyue Li
- Phone Number: +8613902233925
- Email: lishiyue@188.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Not yet recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
Fujian
-
Quanzhou, Fujian, China, 362000
- Not yet recruiting
- The second affiliated hospital, Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- The First Affiliate Hospital of Guangzhou Medical University
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Not yet recruiting
- The First Affiliated Hospital of Suzhou University
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Not yet recruiting
- Shanghai Chest Hospital
-
Shanghai, Shanghai, China, 200433
- Not yet recruiting
- Shanghai pulmonary hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Not yet recruiting
- West China Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Not yet recruiting
- The First Affiliated Hospital, Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years and older;
- Subject presents with PLL(s) detected by chest CT scan and biopsy diagnosis is needed;
- Subject is willing to receive bronchoscopy voluntarily, and meets relevant requirements;
- Subject or their guardian understands the purpose of this trial, and willing to participate in the trial voluntarily and sign Informed Consent Form (ICF).
Exclusion Criteria:
- Subject has participated in a drug or device study (drug study within 3 months or device study within 1 month);
- Female subject who is pregnant or nursing;
- Allergic to anesthetic;
- Bronchoscopy contraindications, include: Active hemoptysis; Newly developed myocardial infarction or unstable angina attack; Severe cardiac and pulmonary dysfunction; Severe hypertension and arrhythmia; Uncorrectable bleeding tendency (Such as severe clotting dysfunction, uremia, and severe pulmonary hypertension, etc.); Severe superior vena cava obstructive syndrome; Suspected aortic aneurysm; Multiple lung bullae; Extremely exhausted systemic conditions;
- Subject with serious lung disease (Such as: severe bronchiectasis, severe emphysema, etc) ,which investigator considers not appropriate for this examination;
- Subject with implanted pacemaker or defibrillator;
- Lack of patient cooperation for bronchoscopy, such as patient with mental disorders, dysgnosia, psychological disorder etc;
- Conditions investigator considers not appropriate for this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ENB-TBLB
Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion.
After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
|
ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools. The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray. TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained. |
ACTIVE_COMPARATOR: X-ray-TBLB
Based on chest CT, the physician determines the lesion location.
Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
|
Based on chest CT, the physician determines the lesion location.
Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the diagnostic yield of ENB-TBLB with that of X-ray-TBLB
Time Frame: Up to 6 months
|
Diagnostic yield = Lesions with definitive diagnosis /total lesions with biopsies. Comment: Lesions with definitive diagnosis: 1. Biopsy pathologic results show as benign or malignant lesion (fungi, tuberculosis, or nodule disease,etc.); 2. Biopsy pathologic results are abnormal lung tissue, but through later diagnosis, treatment and other observation measures, the lesion is proved to be benign; 3. When the patient cannot be diagnosed after a 6-month following-up, a CT or enhanced CT scan is needed and the physician make a final diagnosis based on the scan results. |
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of navigation success
Time Frame: At 1 day of ENB procedure
|
This outcome just apply to experimental group. Incidence of navigation success = the number of lesions navigated successfully/total lesions with ENB procedure × 100%. Criteria for navigation success: When the navigation software shows the distance of location sensor to the target ≤10mm, using X-ray to confirm the actual distance, if the physician determine that biopsy can be conducted, the navigation is successful, if not, the navigation fails. |
At 1 day of ENB procedure
|
Lesion detection rate
Time Frame: About 3-7days after ENB or X-ray procedure
|
Based on the biopsy pathologic results, evaluate the lesion detection rate of experimental and control group. Lesion detection rate = Total lesions detected / Total lesions with biopsies. Comment: 'Lesions detected' indicates pathologic result shows as abnormal lung tissue. |
About 3-7days after ENB or X-ray procedure
|
Navigation time
Time Frame: At 1 day of ENB or X-ray procedure
|
Evaluate navigation time of experimental and control group. Experimental group: After registration, the location sensor returns the carina. Navigation begins from the carina and ends when the sensor reaches the edge of the lesion, which is verified by the X-ray. This period is defined as navigation time of experimental group. Control group: Under X-ray guidance, the bronchoscope moves from the carina to the edge of the lesion. This period is defined as navigation time of control group. |
At 1 day of ENB or X-ray procedure
|
Evaluate the user satisfaction of ENB system and system kit
Time Frame: At 1 day of ENB procedure
|
After each ENB procedure, the investigator evaluate the operational performance of ENB system and system kit through a pre-designed questionnaire which includes terms related to the device function, convenience, reliability and safety.
|
At 1 day of ENB procedure
|
The adverse events and device defects related to the ENB system and system kit
Time Frame: Up to 3 days
|
Adverse events: Include incidence of pneumothorax, bleeding, respiratory failure, etc.
|
Up to 3 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shiyue Li, The First Affiliate Hospital of Guangzhou Medical University
Publications and helpful links
General Publications
- Mahajan AK, Patel S, Hogarth DK, Wightman R. Electromagnetic navigational bronchoscopy: an effective and safe approach to diagnose peripheral lung lesions unreachable by conventional bronchoscopy in high-risk patients. J Bronchology Interv Pulmonol. 2011 Apr;18(2):133-7. doi: 10.1097/LBR.0b013e318216cee6.
- Mukherjee S, Chacey M. Diagnostic Yield of Electromagnetic Navigation Bronchoscopy Using a Curved-tip Catheter to Aid in the Diagnosis of Pulmonary Lesions. J Bronchology Interv Pulmonol. 2017 Jan;24(1):35-39. doi: 10.1097/LBR.0000000000000326.
- Lamprecht B, Porsch P, Wegleitner B, Strasser G, Kaiser B, Studnicka M. Electromagnetic navigation bronchoscopy (ENB): Increasing diagnostic yield. Respir Med. 2012 May;106(5):710-5. doi: 10.1016/j.rmed.2012.02.002. Epub 2012 Mar 3.
- Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e142S-e165S. doi: 10.1378/chest.12-2353.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LHCTP001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Lesion(s) Requiring Evaluation
-
Medtronic - MITGCompletedLung Lesion(s) Requiring EvaluationUnited States, United Kingdom, Italy, Spain, Austria, Denmark, France
-
Duke UniversityCompletedSuspicious Skin Lesion(s) Requiring a BiopsyUnited States
-
Veran Medical TechnologiesCompletedPulmonary Nodule, Solitary | Pulmonary Metastasis | Peripheral Lung Lesions | Lung Lesion(s) Requiring EvaluationUnited States
-
Johns Hopkins UniversityCompletedConditions Requiring Diagnostic EvaluationUnited States
-
Boston Scientific CorporationBeth Israel Deaconess Medical Center; Quintiles, Inc.; Medstar Health Research... and other collaboratorsCompletedAtherosclerotic Lesion(s)New Zealand, Singapore, Australia, Japan
-
Kantonsspital LiestalCompletedBenign or Early Malignant Lesion of the Distal Esophagus or Gastro-esophageal Junction Requiring Surgical ResectionSwitzerland
-
Northwestern UniversityCompletedDiagnostic Self Evaluation | Lesion; PigmentUnited States
-
VIVA PhysiciansPrairie Education and Research Cooperative; Lumen BiomedicalUnknownRenal Stenting in the Treatment of Pts w/a High Grade Ostial Atherosclerotic Renal Lesion(s).United States
-
Centre Hospitalier Universitaire, AmiensCompletedTransbronchial Biopsies | Peripheral Lung LesionFrance
-
Columbus Regional HealthCompletedLung Mass | Lung Nodule | Lesion of the LungUnited States
Clinical Trials on ENB-TBLB
-
Shanghai Chest HospitalFudan UniversityCompleted
-
China-Japan Friendship HospitalNot yet recruitingPulmonary Fibrosis | Transbronchial Cryobiopsy
-
Shanghai Chest HospitalUnknown
-
Shanghai Chest HospitalUnknown
-
University of CalgaryCompletedLung Cancer | Solitary Pulmonary NoduleCanada
-
Shanghai Chest HospitalXiangya Hospital of Central South University; Air Force Military Medical University...Unknown
-
Shanghai Chest HospitalXiangya Hospital of Central South University; Air Force Military Medical University...Completed
-
Medtronic - MITGCompletedLung Lesion(s) Requiring EvaluationUnited States, United Kingdom, Italy, Spain, Austria, Denmark, France
-
Leiden University Medical CenterCompletedSarcoidosisBelgium, United Kingdom, Germany, Denmark, Netherlands, Poland